Medroxyprogesterone Acetate

Endometrial Hyperplasia, Endometriosis, Chronic Pain + 18 more

Treatment

7 FDA approvals

20 Active Studies for Medroxyprogesterone Acetate

What is Medroxyprogesterone Acetate

Medroxyprogesterone acetate

The Generic name of this drug

Treatment Summary

Medroxyprogesterone acetate (MPA) is a hormone-based medication that has an improved resistance to being broken down in the body. It is used to treat various conditions, such as abnormal menstrual bleeding, menopause symptoms, endometrial hyperplasia, endometriosis pain, and prevent pregnancy. It is also used to treat cancer and osteoporosis. MPA was approved by the FDA in 1959.

Medroxyprogesterone Acetate

is the brand name

image of different drug pills on a surface

Medroxyprogesterone Acetate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Medroxyprogesterone Acetate

Medroxyprogesterone acetate

1959

139

Approved as Treatment by the FDA

Medroxyprogesterone acetate, also known as Medroxyprogesterone Acetate, is approved by the FDA for 7 uses such as Vasomotor Symptoms Associated With Menopause and Vulvo Vaginal Atrophy .

Vasomotor Symptoms Associated With Menopause

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Vulvo Vaginal Atrophy

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Postmenopausal Osteoporosis

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Hot flashes

Used to treat Menopause in combination with Conjugated estrogens

Hot Flashes

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Osteoporosis, Postmenopausal

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Atrophic

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Effectiveness

How Medroxyprogesterone Acetate Affects Patients

Medroxyprogesterone acetate (MPA) works by stopping the production of certain hormones and reducing the presence of estrogen in the body. Depending on the form, it can last a long time in the body, from one day to several weeks. Doses of MPA range from 5mg taken orally daily to 1000mg as a weekly shot. Unfortunately, long-term use of MPA has been linked to reduced bone density, especially in adolescents, which can lead to increased risk of osteoporosis and fractures later in life.

How Medroxyprogesterone Acetate works in the body

Medroxyprogesterone acetate (MPA) stops ovulation and thins the endometrium, making it an effective form of contraception. It also affects the endometrium by reducing the number of estrogen receptors and the amount of DNA it produces. MPA can also cause certain cancer cells to die and blocks GABA-A receptors.

When to interrupt dosage

The recommended dosage of Medroxyprogesterone Acetate is contingent upon the discerned condition, including Hormonal Contraception, Amenorrhea and Postmenopausal Osteoporosis. The amount of dosage is dependent on the administration technique (e.g. Tablet - Oral or Intramuscular) provided in the table below.

Condition

Dosage

Administration

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Chronic Pain

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Amenorrhea

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

conjugated estrogen

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

hypoestrogenism

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Birth Control

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometrial Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Fracture

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis, Postmenopausal

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Estrogen Replacement Therapy

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot Flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Uterine hemorrhage

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Atrophic

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hormonal Contraception

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Kidney Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Warnings

Medroxyprogesterone Acetate Contraindications

Condition

Risk Level

Notes

Thromboembolism

Do Not Combine

Breast

Do Not Combine

Thrombophlebitis

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Breast

Do Not Combine

Breast Cancer

Do Not Combine

Stroke

Do Not Combine

Vascular Diseases

Do Not Combine

Thromboembolism

Do Not Combine

Liver Disease

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

suspected pregnancy

Do Not Combine

Disease

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Medroxyprogesterone Acetate may interact with Pulse Frequency

There are 20 known major drug interactions with Medroxyprogesterone Acetate.

Common Medroxyprogesterone Acetate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Medroxyprogesterone acetate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Medroxyprogesterone acetate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Medroxyprogesterone acetate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Medroxyprogesterone acetate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Medroxyprogesterone acetate.

Medroxyprogesterone Acetate Toxicity & Overdose Risk

The lowest toxic dose of medroxyprogesterone acetate in rats has been found to be greater than 6400mg/kg and greater than 16g/kg in mice. Overdosing on MPA may cause nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and menstrual bleeding. If a patient receives too much of a MPA injection, they should seek medical help immediately. Treatment involves stopping the MPA and providing symptomatic care.

image of a doctor in a lab doing drug, clinical research

Medroxyprogesterone Acetate Novel Uses: Which Conditions Have a Clinical Trial Featuring Medroxyprogesterone Acetate?

406 active clinical trials are presently assessing the potential of Medroxyprogesterone Acetate for the management of Osteoporosis, Amenorrhea and Hormonal Contraception.

Condition

Clinical Trials

Trial Phases

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Osteoporosis

27 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Endometrial Neoplasms

0 Actively Recruiting

Fracture

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Birth Control

22 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Estrogen Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot Flashes

4 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Kidney Neoplasms

35 Actively Recruiting

Phase 1, Phase 3, Phase 2, Not Applicable

conjugated estrogen

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

hypoestrogenism

1 Actively Recruiting

Phase 4

Atrophic

4 Actively Recruiting

Phase 4, Not Applicable

Amenorrhea

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Endometrial Hyperplasia

4 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Medroxyprogesterone Acetate Reviews: What are patients saying about Medroxyprogesterone Acetate?

5

Patient Review

10/11/2019

Medroxyprogesterone Acetate for Abnormal Uterine Bleeding caused by Imbalance of Hormones

This medication has helped me to regulate my periods. The only downside is that it makes me feel drowsy.

5

Patient Review

10/21/2020

Medroxyprogesterone Acetate for Absence of Menstrual Periods in Woman Who Has Had Them

Provera completely jumpstarted my period after three months of no activity. I was on day 8 when it finally arrived, and have been very pleased with the results.

5

Patient Review

4/28/2018

Medroxyprogesterone Acetate for Absence of Menstrual Periods in Woman Who Has Had Them

This drug was very effective in inducing a period. I took it for ten days and started my period around day seven or eight. It lasted for fourteen days. The second time I took this drug was for five days at 10mg to start a period and then take clomid. My period started three days after finishing the prescription. Besides mild cramping, I had no side effects, which is unusual for me when it comes to periods.

5

Patient Review

3/15/2021

Medroxyprogesterone Acetate for Absence of Menstrual Periods in Woman Who Has Had Them

I'm on my second round of this medication. I have abnormal periods; I will ovulate but not shed the lining. Last year, when taking this medication, I did bleed heavily and have larger clots. But that was because I was getting rid of months of lining. I had mild cramping, which is normal for me. We are trying to conceive but no luck. Hoping this works as well as it did the first time.

3.7

Patient Review

5/30/2019

Medroxyprogesterone Acetate for Absence of Menstrual Periods in Woman Who Has Had Them

I was prescribed this medication for heavy menstrual bleeding, and it definitely helped to lighten my flow and reduce the amount of blood clots. However, my period lasted longer than usual (nine days instead of the seven), which was a bit inconvenient.

3.7

Patient Review

5/28/2021

Medroxyprogesterone Acetate for Prevention of Abnormal Growth in Cells of Uterine Lining

I had heavy, long periods for a few years before my doctor recommended a D&C. I started taking PROVERA for 10 days, and on the 10th day I started spotting. The bleeding became heavier and then I was rushed to the ER because I felt weak and dizzy. My hemoglobin levels were very low, but after getting 2 units of blood and 3L of fluids, the bleeding stopped.

3.7

Patient Review

10/26/2022

Medroxyprogesterone Acetate for Abnormal Uterine Bleeding caused by Imbalance of Hormones

I've only been taking this medication for a few days, and it has already successfully stopped my period. However, I have started to feel nauseous since the third day of taking it, and this feeling is getting worse as time goes on.

3.3

Patient Review

7/11/2022

Medroxyprogesterone Acetate for Abnormal Uterine Bleeding caused by Imbalance of Hormones

My gynecologist prescribed this to me in order to stop the bleeding that started six years after my uterus was ablated. So far, it's been successful in keeping the bleeding at bay; however, I have been feeling extra tired and crampy. I'm hoping this will stop soon.

3

Patient Review

6/6/2022

Medroxyprogesterone Acetate for Test for the Presence of Estrogen in the Body

My OBGYN prescribed this medication for me to use over the course of 90 days in order to help regulate my irregular menstrual cycles. I was told that it would lighten my flow, which it has done; however, I've been bleeding and spotting for 3 weeks straight now, which is a bit much. Additionally, I've experienced mood swings and constant thirstiness since starting the medication.

3

Patient Review

8/17/2022

Medroxyprogesterone Acetate for Absence of Menstrual Periods in Woman Who Has Had Them

I started taking this medication yesterday because I have PCOS, and I've been experiencing a lot of pelvic and lower back pain. So far, I haven't seen any results, but I'm hopeful that this will help me to become more regular again.

2.7

Patient Review

1/10/2022

Medroxyprogesterone Acetate for Prevention of Abnormal Growth in Cells of Uterine Lining

Though it did what it was supposed to do in terms of stopping my heavy bleeding, I found the side effects really intolerable.

2.3

Patient Review

7/23/2020

Medroxyprogesterone Acetate for Abnormal Uterine Bleeding caused by Imbalance of Hormones

I was prescribed this medication on 5/29 and have been bleeding for 55 days straight. I went back to the doctor and all they offered me was a dnc.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about medroxyprogesterone acetate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is medroxyprogesterone used for abortion?

"MPA was found to be not significantly different and is considered to be safe to use during pregnancy. It is unlikely to cause an abnormal fetus or lead to a miscarriage. Although this report does not address how effective MPA is, it seems to be a safe drug to use during pregnancy."

Answered by AI

What are the side effects of medroxyprogesterone acetate?

"If you experience any of the following side effects, tell your doctor or pharmacist: nausea, bloating, breast tenderness, headache, change in vaginal discharge, mood swings, blurred vision, dizziness, drowsiness, or weight gain/loss."

Answered by AI

Is medroxyprogesterone a steroid?

"Medroxyprogesterone is a synthetic progestin and oral contraceptive. It is structurally similar to the hormone progesterone and is used for a variety of purposes including contraception, menopausal hormone therapy, and treatment of endometriosis."

Answered by AI

Clinical Trials for Medroxyprogesterone Acetate

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Have you considered Medroxyprogesterone Acetate clinical trials?

We made a collection of clinical trials featuring Medroxyprogesterone Acetate, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Medroxyprogesterone Acetate clinical trials?

We made a collection of clinical trials featuring Medroxyprogesterone Acetate, we think they might fit your search criteria.
Go to Trials
Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Have you considered Medroxyprogesterone Acetate clinical trials?

We made a collection of clinical trials featuring Medroxyprogesterone Acetate, we think they might fit your search criteria.
Go to Trials